Aryl coupling reactions of pyrazolo[3,4-d]pyrimidin-4-yl radicals
作者:Jeffery B. Press、Nancy H. Eudy、George O. Morton
DOI:10.1021/jo00172a033
日期:1983.12
USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER
申请人:Del Mar Pharmaceuticals
公开号:EP3125920A2
公开(公告)日:2017-02-08
[EN] USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER<br/>[FR] UTILISATION DE DIANHYDROGALACTITOL ET DE LEURS ANALOGUES OU DÉRIVÉS DANS LE TRAITEMENT DU CARCINOME NON À PETITES CELLULES DES POUMONS ET DU CANCER DES OVAIRES
申请人:DEL MAR PHARMACEUTICALS
公开号:WO2015154064A2
公开(公告)日:2015-10-08
The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and thymidine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.